Drug profile

The FDA adverse-event record for Hyaluronic Acid

274 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Hyaluronic Acid. See the species affected, top reactions, and outcomes below.

274
adverse-event reports
2.9%
death-coded share
Unknown
most-reported species
19
Corneal ulcer - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
274
Total Reports
8
Deaths Reported
2.9%
Death Rate

Active Ingredients

Hyaluronic Acid

Administration Routes

UnknownIntra-ArticularOphthalmicOralParenteralIntraocular

Species Affected

Unknown 140
Dog 86
Horse 35
Cat 9
Human 2
Guinea Pig 1
Other 1

Most Affected Breeds

Unknown 144
Quarter Horse 14
Crossbred Canine/dog 12
Shih Tzu 9
Chihuahua 7
Retriever - Labrador 5
Crossbred Equine/horse 5
Domestic Shorthair 5
Warmblood (unspecified) 5
Pug 5

Most Reported Reactions

Corneal ulcer 19
Ocular discharge 17
Underfilling, Bottles 16
Solution, Abnormal 15
Diarrhoea 13
Dispenser, Abnormal 13
Eye pain 13
Lethargy (see also Central nervous system depression in 'Neurological') 13
Other abnormal test result NOS 13
Behavioural disorder NOS 13
Applicator, Abnormal 13
Underfilling, Package 12

Outcome Breakdown

Recovered/Normal
55 (40.7%)
Outcome Unknown
54 (40.0%)
Ongoing
13 (9.6%)
Recovered with Sequela
5 (3.7%)
Euthanized
4 (3.0%)
Died
4 (3.0%)

Hyaluronic Acid Adverse Event Insights

274 reports name Hyaluronic Acid; 8 recorded a death outcome (2.9% of reported events, not a population-level mortality rate). Active ingredient: Hyaluronic Acid. Administration routes: Unknown, Intra-Articular, Ophthalmic, Oral.

By species: Unknown (140 reports), Dog (86 reports), Horse (35 reports). By breed: Unknown (144), Quarter Horse (14), Crossbred Canine/dog (12).

Leading clinical signs: Corneal ulcer (19), Ocular discharge (17), Underfilling, Bottles (16), Solution, Abnormal (15). Outcome, 135 coded reports: Recovered/Normal leads at 40.7%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.